Coronary heart disease (CHD) is a major cause of morbidity and mortality worldwide.
Elevated low density lipoprotein-cholesterol (LDL-C) and reduced high density lipoprotein …

A large body of evidence has demonstrated that reductions in low‐density lipoprotein
cholesterol (LDL‐C) decrease the risk of coronary heart disease (CHD) and related adverse …

Lipid-lowering guidelines continue to evolve toward the use of (1) global risk assessment,(2)
lipid measures other than or in addition to low-density lipoprotein (LDL) cholesterol in …

The benefit of cholesterol-lowering therapy in the prevention of coronary heart disease
(CHD) is well established. The secondary prevention Scandinavian Simvastatin Survival …

The primary aim of lipid-related cardiovascular disease (CVD) risk management is the
lowering of LDL-C levels. Numerous studies have shown that statins, which inhibit …

Overwhelming evidence from epidemiological and clinical studies has demonstrated that
low density lipoprotein cholesterol (LDL-C) is a key element in the development of …

The aim of pharmacological lipid modification is to reduce low-density lipoprotein
cholesterol (LDL-C) as a means of either secondary or primary prevention of cardiovascular …

Background and aims Guidelines for cholesterol-lowering medication either advocate fixed
dose statin treatment without low density lipoprotein (LDL) cholesterol targets or treatment …

The evidence from trials of statin therapy suggests that benefits in cardiovascular disease
(CVD) event reduction are proportional to the magnitude of low-density lipoprotein …

Control of lipid levels is one of the most effective strategies for cardiovascular (CV) event
prevention. In fact, many clinical trials have clearly demonstrated that low-density lipoprotein …